By Chris Wack

 

Argenx shares were up 25% to $474.87 in premarket trading after the company said it and Zai Lab saw positive topline results from their study evaluating Vyvgart Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with chronic inflammatory demyelinating polyneuropathy.

Zai Lab shares were up 10% to $30.49 in premarket trading.

The companies said the study met its primary endpoint, demonstrating a significantly lower risk of relapse with Vyvgart Hytrulo compared with placebo.

The study showed that the safety and tolerability profile was consistent with confirmed safety profile of Vyvgart, and 91% of eligible patients continued to the next phase of the open-label extension study.

The most frequent treatment-related adverse event was injection site reactions, which occurred in a lower percentage of patients than previous Vyvgart Hytrulo trials. All injection site reactions were mild to moderate and resolved over time.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

July 17, 2023 06:55 ET (10:55 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
argenx (NASDAQ:ARGX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 argenx 차트를 더 보려면 여기를 클릭.
argenx (NASDAQ:ARGX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 argenx 차트를 더 보려면 여기를 클릭.